Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 19th October, 2023 has inter-alia considered and approved the following. 1. Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September, 2023 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. 2. Issuance of a Corporate Guarantee of Rs. 17,00,00,000 in favour of Citibank N.A. in respect of the working capital facilities to be availed by Florida Pharmaceutical Products LLC, step down subsidiary of the Company.